uniQure N.V.

QURE

NASDAQ

Healthcare

Biotechnology

Amsterdam, NL209 employeesuniqure.com

$17.15

+0.26(1.55%)

Mkt Cap $1.1B

$8.34

$70.59

52-Week Range

At A Glance

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.

Revenue is primarily driven by Contract Manufacturing Revenue (53.1%) and License (32.1%).

Most recently: , including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or o (2026-03-02).

$1.1B

Market Cap

$17M

Revenue

-$213M

Net Income

Employees209

Fundamentals

How The Business Makes Money

Revenue by Segment

Contract Manufacturing Revenue53.1%($48M)

License32.1%($29M)

Collaborative Revenue14.8%($13M)

Activity

What Changed Recently

Financial Results

Mar 1, 2026

, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or o

Regulation FD

Jan 12, 2026

, including the accompanying Exhibit 99.1, shall be deemed “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange

Regulation FD

Jan 8, 2026

, including the accompanying Exhibit 99.1, shall be deemed “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange

Company Profile

CIK0001590560

ISINNL0010696654

CUSIPN90064101

Phone31 20 240 6000

AddressPaasheuvelweg 25a, Amsterdam, 1105 BP, NL

SEC EDGAR